Journey Life Sciences is focused on developing and commercializing therapeutic treatments for chronic pain through the use of psychoactive compounds with the potential to solve the opioid epidemic.

YPO (formerly Young Presidents' Organization) is an American-based worldwide leadership community of chief executives with more than 34,000 global members in more than 142 countries.

The Modern Health Alliance (MHA) was an advocacy organization championing the benefits of new medicines. We do this by supporting legislation + policies that promote research, education and product development.

Bonaventure Equity is a life sciences venture capital firm investing in cannabinoid and psychedelic innovation. BVE partners with dynamic founders and management teams at the forefront of scientific breakthroughs on the path to commercialization.

Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.

Publicly-traded CSE: TRYP is a clinical stage pharmaceutical company leading psychedelic drug development beyond mental health.

Torrent Ventures supports companies pursuing the most dynamic healthcare and medical technology opportunities. The firm has deep relationships with corporate and academic centers of innovation for drug development, genomics, diagnostics, medical devices and precision medicine technologies.

CONNECT is a southern California based business accelerator focused on creating and scaling technology and life science start-ups. Initially affiliated with the University of California, San Diego, CONNECT has served over 4,000 companies which have raised over $1.2 billion. CONNECT Springboard graduate companies are on track to generate over $500 million in revenue and have generated $2.3B in exits since 2005.

Akela Pharma Inc. was an Austin, Texas based, Toronto Stock Exchange listed (AKL:TO) drug development company and contract manufacturing organization Akela’s lead compound, Fentanyl TAIFUN, was a Phase 3 ready, novel, inhaled version of Fentanyl being developed for break-through cancer pain. Akela’s, CMO, PharmaForm, had capabilities to manufactures Phase 1 through Phase 3 clinical trial materials, as well as small scale commercial drug product supplies for its clients. In 2011, Pharamform generated $10 million in revenue and over $1.5 million in EBITDA.

Nventa Biopharmaceuticals Corporation was a development stage drug development company focusing on developing innovative therapeutic vaccines for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company’s lead candidate, HspE7, was a novel therapeutic vaccine intended for the treatment of HPV-related diseases. HspE7 is derived from Nventa’s proprietary CoVal™ fusion platform that uses recombinant DNA technology to covalently fuse heat shock proteins to target antigens, thereby stimulating cellular immune system responses to specific diseases. Nventa was developing HspE7 in combination with Poly-ICLC, an adjuvant that activates innate immunity, for multiple indications. Headquartered in San Diego, CA, Nventa Common Stock traded on the Toronto Stock Exchange (TSX) under the symbol: NVN until acquired by Akela Pharm, Inc. in May 2009. Akela Pharma was taken private in 2012.

Valentis was a biopharmaceutical company with a significant body of non-viral gene delivery patents used in combination with specific genes to treat Cardiovascular disease and certain oncology indications.

Director - Asia Genzyme International (Singapore)Based in Singapore, responsible for the overall business strategy and implementation for the Company’s South East Asia region for the Therapeutics and BioSurgical Products business units. Lead multinational team with highly diverse backgrounds, including one PhD, one Korean, one Taiwanese, one Australian, and two Singaporeans. Managed broad geographic territory including product sales in the countries of Hong Kong, People’s Republic of China, Singapore, South Korea, Taiwan, and Thailand. Developed and managed approximately $5.0 million in revenues from the Specialty Therapeutics business, including launching and managing the Company’s lead product targeting the treatment of Gaucher Disease, Cerezyme. Successfully restructured and managed a twelve company surgical products distribution network in the region, generating $1.1million in revenues. Assisted in completion of a $50 million in-licensing agreement with a Taiwanese pharmaceutical company. Team captured two of three top International Division Awards in 1999.

Employed by The Honorable Taro Nakayama immediately following his reign as Minister for Foreign Affairs of Japan. Served as the only non-Japanese member of staff, with main oversight of the Minister’s international portfolio, including advising the United Nations sponsored Inter-Action Council; developing the International Medical Parliamentarians Organization; assisting in the organization of two successful national level election campaigns. Assisted in the development of the Japan-Russia Medical Exchange Foundation. Provided advisory briefings on international policy issues including those for meetings with James Baker III, Henry Kissinger, Helmut Schmidt, and Eduard Shevardnadze. Frequently translated for Minister Nakayama or his wife, Hanako.Taro Nakayama (中山 太郎), born August 27, 1924 is a Japanese doctor and politician serving in the House of Representatives in the Diet (national legislature) as a member of the Liberal Democratic Party. A native of Osaka he received a Ph.D in medicine from Osaka Medical College in 1960 for the study of infantile paralysis. After serving in the assembly of Osaka Prefecture he was elected to the Diet for the first time in 1968 as a member of the House of Councilors and to the House of Representatives for the first time in 1986. From 1989 to 1990 he served as Minister of Foreign affairs in Toshiki Kaifu's cabinet (1989–1991).

First member of Japanese derivative product sales and trading team and one of eight on Japanese Equity desk in UBS Warburg’s Tokyo-based investment banking operation. Responsible for establishing relationships and generating sales and trading revenues from non-Japanese based investors in Tokyo, Hong Kong, and New York. Assisted in the development of the Company’s first proprietary quantitative derivative analytical research tool. Generated a $1 million base of sales and trading revenue after two years.

First non-Japanese staff member of the Japanese Equity Desk within the Company’s Pension Fund Management Department, responsible for the management of Japanese equity portfolios valued at $550 million.